Overview

Effect of Boceprevir on HCV-specific T Cell Responses

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Analysis of HCV-specific T cell responses in patients treated with boceprevir to assess whether therapy can induce restoration of the T cell function and to what extent this recovery can be achieved
Details
Lead Sponsor:
Azienda Ospedaliero-Universitaria di Parma
Treatments:
Peginterferon alfa-2b
Ribavirin